News

Concerns Raised by APhA on CDC's Hepatitis B Vaccine Guidelines

Concerns Raised by APhA on CDC's Hepatitis B Vaccine Guidelines

APhA Expresses Concerns Over Changes in Hepatitis B Vaccine Policy

The American Pharmacists Association (APhA) has voiced significant concern regarding the recent decision made by the CDC's Advisory Committee on Immunization Practices (ACIP) to eliminate the universal recommendation for administering the hepatitis B vaccine birth dose for infants in the United States. This decision represents a considerable step back from a successful public health initiative that has been in effect since 1991.

The introduction of the universal birth-dose recommendation has resulted in a significant decline in acute hepatitis B virus (HBV) infections among infants and young children. This change is crucial as it has been instrumental in preventing numerous children from developing chronic infections that could lead to serious health implications later in life. The hepatitis B vaccine is recognized for its safety and effectiveness, serving as the most reliable approach to avert chronic HBV infections. Even infants born to mothers who do not carry HBV are still at risk due to potential exposure from infected individuals in their homes, such as caregivers and siblings. This highlights the essential role of universal vaccination.

Brigid Groves, PharmD, MS, the vice president of professional affairs at APhA, stated, "Pharmacists have long been involved in preventing disease transmission through vaccine advocacy and administration, including the hepatitis B vaccine. We remain committed to safeguarding patients throughout their lives. The scientific evidence underscores that administering the hepatitis B birth dose saves lives, and no new data supports the withdrawal of this vital protection."

It is alarming to note that newborns infected with HBV have a 90% chance of becoming chronic carriers. Furthermore, one out of four infants diagnosed at birth may ultimately die due to HBV-related liver complications or liver cancer. Young children who contract HBV face an alarming 20% to 50% risk of developing a lifelong chronic infection. These severe consequences, along with the extensive treatments they necessitate, can be effectively prevented through timely vaccination.

APhA advocates strongly for maintaining the established and evidence-based childhood immunization schedule, which includes the HepB birth dose that has consistently demonstrated both safety and effectiveness.

The Importance of Hepatitis B Vaccination in Adults

Beyond childhood vaccinations, APhA emphasizes the necessity of hepatitis B vaccination for adults as well. The ACIP continues to advocate for the vaccination series for all individuals aged 19 to 59, older adults with specific risk factors, and any adult expressing a desire to get vaccinated. Hepatitis B vaccines are safe, effective, and generally covered by health insurance plans.

APhA's Ongoing Commitment

The APhA will persist in its advocacy for evidence-based immunization policies that prioritize the health and safety of patients and communities across the nation. Their role as a leading voice in pharmacy emphasizes the importance of vaccines in disease prevention, particularly concerning hepatitis B.

About the American Pharmacists Association

The APhA stands as the singular organization dedicated to advancing the pharmacy profession as a whole. Based in Washington, DC, APhA takes the lead in supporting pharmacists, student pharmacists, and pharmacy technicians in optimizing medication use and enhancing patient health outcomes. They ensure that patients have access to pharmacists' expertise and care through effective advocacy, high-quality education, practical tools and resources, the dissemination of scientific evidence, and opportunities for collaboration among members.

APhA represents the pharmacy profession at the national level, contributing to the development of guidelines, policies, and best practices aimed at elevating the profession while improving patient care throughout the community.

Frequently Asked Questions

Why is the APhA concerned about the hepatitis B vaccination decision?

The APhA believes the removal of the universal birth dose puts infants at risk who could otherwise benefit from this important vaccination.

What are the risks associated with hepatitis B in infants?

Infants infected with HBV have a high chance of becoming chronic carriers and facing severe health complications, including liver failure and cancer.

What role do pharmacists play in vaccination?

Pharmacists are vital in administering vaccines and educating the public about vaccine benefits, including hepatitis B vaccination.

How safe are the hepatitis B vaccines?

Hepatitis B vaccines are well-established and recognized for their safety and effectiveness across various age groups.

What can be done to support childhood vaccination efforts?

Advocacy for evidence-based immunization policies, community education, and strong support for the established immunization schedule can enhance vaccination efforts.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 9

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 84

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 89

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 119

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 156

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 179

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 132

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading

Top 5 Most Recently Viewed Articles

Social Media Buzz Powers Hainan's Travel Boom

Updated Category News Views 205

Social Media Buzz Powers Hainan's Travel Boom This year marks a remarkable shift in Hainan's tourism, driven by the advent of visa-free travel access for international visitors. As the beautiful island in southern China opens its doors wider, a surge in travelers, especially travel bloggers from around the globe, is noticeable. Influencers from diverse backgrounds,...

Continue Reading
Kodiak Sciences Reports Q3 2025 Financial Milestones and Updates

Updated Category News Views 375

Kodiak Sciences Reports Q3 2025 Financial Milestones and Updates Kodiak Sciences Inc. (Nasdaq: KOD) has recently shared significant business highlights along with financial results for the third quarter of 2025. This biotechnology company is making strides in the field of retinal medicine. 'We are witnessing a period marked by sustained momentum,' expressed Victor...

Continue Reading
Vaisala Initiates Share Repurchase Program to Enhance Incentives

Updated Category News Views 193

Vaisala’s Strategy for Share Repurchases Vaisala Corporation is embarking on an important journey to repurchase its own shares as part of a broader incentive plan. This strategic decision follows the authorization granted by the Annual General Meeting, reflecting the company's commitment to fostering a rewarding environment for its employees. As a key player in climate...

Continue Reading
Investigating Customer Bancorp, Inc. Losses: Understand Your Rights

Updated Category News Views 92

Exploring Customers Bancorp, Inc.'s Recent Challenges Customers Bancorp, Inc., identified by the ticker CUBI, is dealing with significant accusations regarding the truthfulness of the business information it has shared with the public. The Rosen Law Firm, a respected advocate for investor rights, is currently looking into securities claims tied to these allegations. If...

Continue Reading
Allurity and Onevinn: Transforming Cybersecurity Together

Updated Category News Views 374

Allurity Expands its Cybersecurity Portfolio with Onevinn Acquisition Allurity, a prominent European provider of cybersecurity services, has exciting news to share. The company has taken a significant step forward by acquiring Onevinn, a Swedish company renowned for its intelligent security and managed services. This move not only showcases Allurity's ambitions but also...

Continue Reading